Search research articles
Contact Us
Filters
Showing results (1-10 of 11) with videos related to
Page
of 2
Sort By:
Current Treatment Options in Oncology
|
June 12, 2002
Advanced renal cell carcinoma
M I Milowsky, D M Nanus
Clinical Pharmacology and Therapeutics
|
September 3, 2015
Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistance
D J Crona, M I Milowsky, Y E Whang
Cancer Research
|
April 20, 2001
Neutral endopeptidase inhibits neuropeptide-mediated transactivation of the insulin-like growth factor receptor-Akt cell survival pathway
M Sumitomo, M I Milowsky, R Shen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 7, 2008
Detection of circulating tumor cells in patients with urothelial cancer
D J Gallagher, M I Milowsky, N Ishill, et al.
Clinical Radiology
|
May 27, 2018
Integrative radiomics expression predicts molecular subtypes of primary clear cell renal cell carcinoma
Q Yin, S-C Hung, W K Rathmell, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 13, 2023
Pemigatinib for metastatic or surgically unresectable urothelial carcinoma with FGF/FGFR genomic alterations: final results from FIGHT-201
A Necchi, D Pouessel, R Leibowitz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 31, 2013
Germline single nucleotide polymorphisms associated with response of urothelial carcinoma to platinum-based therapy: the role of the host
D J Gallagher, J Vijai, R J Hamilton, et al.
World Journal of Urology
|
June 26, 2016
Upper tract urothelial carcinoma topical issue 2016: treatment of metastatic cancer
M N Pham, A B Apolo, M De Santis, et al.
Clinical Genitourinary Cancer
|
July 5, 2014
Impact of the number of prior lines of therapy and prior perioperative chemotherapy in patients receiving salvage therapy for advanced urothelial carcinoma: implications for trial design
G R Pond, J Bellmunt, J E Rosenberg, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 19, 2025
Adjuvant nivolumab versus placebo for high-risk muscle-invasive urothelial carcinoma: 5-year efficacy and ctDNA results from CheckMate 274
M D Galsky, J E Gschwend, M I Milowsky, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 11) with videos related to
Sort By:
Page
of 2
Current Treatment Options in Oncology
|
June 12, 2002
Advanced renal cell carcinoma
M I Milowsky, D M Nanus
Clinical Pharmacology and Therapeutics
|
September 3, 2015
Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistance
D J Crona, M I Milowsky, Y E Whang
Cancer Research
|
April 20, 2001
Neutral endopeptidase inhibits neuropeptide-mediated transactivation of the insulin-like growth factor receptor-Akt cell survival pathway
M Sumitomo, M I Milowsky, R Shen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 7, 2008
Detection of circulating tumor cells in patients with urothelial cancer
D J Gallagher, M I Milowsky, N Ishill, et al.
Clinical Radiology
|
May 27, 2018
Integrative radiomics expression predicts molecular subtypes of primary clear cell renal cell carcinoma
Q Yin, S-C Hung, W K Rathmell, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 13, 2023
Pemigatinib for metastatic or surgically unresectable urothelial carcinoma with FGF/FGFR genomic alterations: final results from FIGHT-201
A Necchi, D Pouessel, R Leibowitz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 31, 2013
Germline single nucleotide polymorphisms associated with response of urothelial carcinoma to platinum-based therapy: the role of the host
D J Gallagher, J Vijai, R J Hamilton, et al.
World Journal of Urology
|
June 26, 2016
Upper tract urothelial carcinoma topical issue 2016: treatment of metastatic cancer
M N Pham, A B Apolo, M De Santis, et al.
Clinical Genitourinary Cancer
|
July 5, 2014
Impact of the number of prior lines of therapy and prior perioperative chemotherapy in patients receiving salvage therapy for advanced urothelial carcinoma: implications for trial design
G R Pond, J Bellmunt, J E Rosenberg, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 19, 2025
Adjuvant nivolumab versus placebo for high-risk muscle-invasive urothelial carcinoma: 5-year efficacy and ctDNA results from CheckMate 274
M D Galsky, J E Gschwend, M I Milowsky, et al.
Page
of 2